Skip to main content

Table 1 Clinical characteristics of the study population (N = 218 patients)

From: Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: a French multicentre observational study

Initial diagnosis  
Median age at BC diagnosis (years, range) 51 (24-81)
Invasive ductal carcinoma (patients, %) 202/218 (92.7%)
Median tumour size (mm, range) 25 mm (1-200)*
Presence of lymph node involvement (evaluable tumours, %) 72/134 evaluable tumours (53.7%)
Oestrogen receptor-positive (patients, %) 93/192* (48.4%)
Progesterone receptor-positive (patients, %) 60/164* (36.6%)
Treatments before CNS metastases  
Chemotherapy before CNS metastases (patients, %) 210/218 (96.3%)
  HER2-targeted therapy before CNS metastases (patients, %) 197/218 (90.4%)
  Bevacizumab before CNS metastases (patients, %) 3/218 (1.4%)
  Hormone therapy before CNS metastases (patients, %) (ER and PR positive at initial diagnosis N = 110 patients) 82/110 (74.5%)
Local radiation therapy before CNS metastases (patients, %) 159/218 (72.9%)
Metastatic disease  
Median time to first metastatic relapse, any site (months, range) 21.9 months (0-214.7)
Median time between initial BC diagnosis and CNS metastasis (months, range) 37.6 months (0-286.5)
Median time to first relapse and CNS metastasis (months, range) 12.9 months (0-283.7)
CNS metastasis at first relapse (patients, %) 39/217 (18%)
  Unique first site metastasis 31/217 (14.3%)
Carcinomatous meningitis 28/216 (13%)
CNS metastasis as secondary site (associated with other metastases) 167/218 (76.6%)
Other main metastatic sites at CNS metastasis diagnosis (n = 180)  
  Bone 111/178 (62.4%)
  Lung/pleura 86/178 (48.3%)
  Lymph nodes 101/178 (56.7%)
  Liver 34/178 (19.1%)
Median interval between CNS metastasis and other metastases 5.5 months (0.1-29)
Survival following CNS metastasis  
Median survival for study population (months, range) 13.1 months (11-15.8)
Median survival for CNS metastasis as first site of relapse 14.2 months (10.6-22.2)
Median survival for secondary CNS metastasis (associated with other metastases) 13 months (10.5-15.8)
Death at 2 years (Kaplan-Meier estimate) 70.27
Median time to GPA threshold 1-2/2.5-3/3.5-4 patients  
  Score 1 - 2 10 months
  Score 2.5 - 3 12 months
  Score 3.5 - 4 24 months
  1. *Data was missing for some patients. BC: breast cancer; CNS: central nervous system; GPA: Graded Prognostic Assessment.